Dihexa comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
=== Anaerobic digestion === Anerobic digestion is found in all facets of biomass fermentation to create biofuels, biobased materials, and biochemicals. One of the most popular and established anaerobic fermentation process is the transformation of organic waste into biogas. Further research has explored the possibility and reusing residual solids left over from fermentative processes and converting them into "char-based materials". If successful, this would promote increased efficiency and a decreased environmental impact in the biomanufacturing industry. Additionally, homogenous gas streams of CO2, and CH4, can be formed from anaerobic digestion by some bacteria, while other bacteria are able to fixate CO2 or CO and convert them into alcohols or fatty acids.
=== Schools === Le Havre is located in the Academy of Rouen. The city operates 55 kindergartens (254 classes) and 49 communal primary schools (402 classes). The department manages 16 colleges and the region of Normandy manages 9 schools. The Jules Valles college in Caucriauville is classified as a sensitive institution and eleven colleges are in a priority education zone (ZEP). A boarding school of excellence, the Claude Bernard college, opened in 2011. The first college in Le Havre dates to the 16th century, the high school François I was founded during the Second Empire and is the oldest in Le Havre. The philosopher Jean-Paul Sartre (1905–1980) and Raymond Aron (1905–1983) taught there. The writer Armand Salacrou (1899–1989) studied in this institution.
The bacterial one-hybrid (B1H) system is a method for identifying the sequence-specific target site of a DNA-binding domain. In this system, a given transcription factor (TF) is expressed as a fusion to a subunit of RNA polymerase. In parallel, a library of randomized oligonucleotides representing potential TF target sequences are cloned into a separate vector containing the selectable genes HIS3 and URA3. If the DNA-binding domain (bait) binds a potential DNA target site (prey) in vivo, it will recruit RNA polymerase to the promoter and activate transcription of the reporter genes in that clone. The two reporter genes, HIS3 and URA3, allow for positive and negative selections, respectively. At the end of the process, positive clones are sequenced and examined with motif-finding tools in order to resolve the favoured DNA target sequence.
=== Cooling water systems === Industrial cooling water systems are susceptible to scale formation due to high temperatures and concentrations of dissolved minerals. Antiscalants help mitigate scale deposition in cooling towers, heat exchangers, and condensers, preserving their efficiency and reducing the need for maintenance.
Sources: en.wikipedia.org
== Structure and reactivity == The structure of α-PMTX consists of 13 amino acid residues with the sequence Arg-Ile-Lys-Ile-Gly-Leu-Phe-Asp-Gln-Leu-Ser-Lys-Leu-NH2. Replacement of the lysine residue at position 12 of α-PMTX with arginine results in β-PMTX. This single amino acid difference appears to be responsible for a difference in potency, as β-PMTX appeared to be five times as potent as α-PMTX in lobster neuromuscular junctions. The location of the three basic residues at positions 1, 3 and 12 was found to be crucial for toxin action. The length of the compound also appeared to be crucial for its function. Analogues of α- and β-PMTX have been synthesized by implementing changes in the amino acid sequence to understand the structure-activity relationship (SAR) with respect to activity for human voltage-gated sodium channel 1.1 (hNaV1.1) and selectivity over other isoforms of human Na+ channels such as hNaV1.2-1.7. 3D models have suggested that β-PMTX may adopt a kinked conformation assisted by its Gly-5 residue and is further stabilised by electrostatic interaction between its negatively charged Asp-8 and positively charged residues Arg-1 and/or Lys-3. This led to the hypothesis that a β-turn-like conformation depending on Gly-5, since it is the most sterically flexible amino acid, could be an important feature of the pharmacologically active conformation. This was tested by replacing Gly-5 with other (β-)turn-favouring residues, but this change was not tolerated.
Phenazepam (also known in Russia as bromdihydrochlorphenylbenzodiazepine) is a benzodiazepine drug, first developed in the Soviet Union in 1975, and now produced in Russia and several other countries. Phenazepam is used in the treatment of various mental disorders such schizophrenia and anxiety. It can be used as a premedication before surgery as it augments the effects of anesthetics. In 2009, phenazepam has gained popularity as a recreational drug; misuse has been reported in the United Kingdom, Finland, Sweden, and the United States.
== Pharmacokinetics == A small amount of sulfanilamide is absorbed following topical application or when administered as a vaginal cream or suppository (through the vaginal mucosa). It is metabolized by acetylation like other sulfonamides and excreted through the urine.
=== Heart disease === Abdominal obesity is typically associated with a statistically higher risk of heart disease, hypertension, insulin resistance, and type 2 diabetes (see below). With an increase in the waist to hip ratio and overall waist circumference the risk of death increases as well. Metabolic syndrome is associated with abdominal obesity, blood lipid disorders, inflammation, insulin resistance, type 2 diabetes, and an increased risk of developing cardiovascular disease. It is now generally believed that intra-abdominal fat is the depot that conveys the biggest health risk. Recent validation has concluded that total and regional body volume estimates correlate positively and significantly with biomarkers of cardiovascular risk and that BVI calculations correlate significantly with all biomarkers of cardiovascular risk. Abdominal obesity is linked with higher cardiovascular events among South Asian ethnic populations.
1808: Anna Sundström began assisting Jacob Berzelius in his laboratory, becoming one of the first Swedish women chemists. 1809: Italian pharmacist Sabina Baldoncelli earned her university degree in pharmacy but was allowed to work only in the Italian orphanage where she resided. 1815: English archaeologist and antiquarian Lady Hester Stanhope used a medieval Italian manuscript to locate a promising archaeological site in Ashkelon, becoming the first archaeologist to begin an excavation in the Palestinian region. It was one of the earliest examples of the use of textual sources in field archaeology. 1816: French mathematician and physicist Sophie Germain became the first woman to win a prize from the Paris Academy of Sciences for her work on elasticity theory. 1823: English palaeontologist and fossil collector Mary Anning discovered the first complete Plesiosaurus. 1831: Italian botanist Elisabetta Fiorini Mazzanti published her best-known work Specimen Bryologiae Romanae. 1830–1837: Belgian botanist Marie-Anne Libert published her four-volume Plantae cryptogamicae des Ardennes, a collection of 400 species of mosses, ferns, lichen, algae and fungi from the Ardennes region. Her contributions to systemic cryptogamic studies were formally recognized by Prussian king Friedrich Wilhelm III, and Libert received a gold medal of merit. 1832: French marine biologist Jeanne Villepreux-Power invented the first glass aquarium, using it to assist in her scientific observations of Argonauta argo.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.